CN116531410A - Application of staphylococcus albus in preparation of composition - Google Patents
Application of staphylococcus albus in preparation of composition Download PDFInfo
- Publication number
- CN116531410A CN116531410A CN202310823003.4A CN202310823003A CN116531410A CN 116531410 A CN116531410 A CN 116531410A CN 202310823003 A CN202310823003 A CN 202310823003A CN 116531410 A CN116531410 A CN 116531410A
- Authority
- CN
- China
- Prior art keywords
- staphylococcus albus
- composition
- use according
- medicament
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000191963 Staphylococcus epidermidis Species 0.000 title claims abstract description 41
- 239000000203 mixture Substances 0.000 title claims abstract description 25
- 238000002360 preparation method Methods 0.000 title claims description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract description 33
- 206010022489 Insulin Resistance Diseases 0.000 claims abstract description 28
- 239000003814 drug Substances 0.000 claims abstract description 18
- 102000017011 Glycated Hemoglobin A Human genes 0.000 claims abstract description 10
- 108010014663 Glycated Hemoglobin A Proteins 0.000 claims abstract description 10
- 235000013305 food Nutrition 0.000 claims abstract description 7
- 208000024891 symptom Diseases 0.000 claims abstract description 7
- 230000006872 improvement Effects 0.000 claims description 7
- 230000002496 gastric effect Effects 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 3
- 210000001072 colon Anatomy 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 3
- 239000002417 nutraceutical Substances 0.000 claims description 3
- 235000021436 nutraceutical agent Nutrition 0.000 claims description 3
- 210000000664 rectum Anatomy 0.000 claims description 3
- 230000009467 reduction Effects 0.000 claims description 3
- 210000000813 small intestine Anatomy 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 239000013585 weight reducing agent Substances 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 210000002784 stomach Anatomy 0.000 claims description 2
- 208000002705 Glucose Intolerance Diseases 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 239000012669 liquid formulation Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 201000009104 prediabetes syndrome Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 abstract description 8
- 206010061218 Inflammation Diseases 0.000 abstract description 7
- 230000004054 inflammatory process Effects 0.000 abstract description 7
- 229940079593 drug Drugs 0.000 abstract description 6
- 230000003907 kidney function Effects 0.000 abstract description 5
- 230000037356 lipid metabolism Effects 0.000 abstract description 5
- 230000003908 liver function Effects 0.000 abstract description 5
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 4
- 206010067484 Adverse reaction Diseases 0.000 abstract description 2
- 230000006838 adverse reaction Effects 0.000 abstract description 2
- 210000004185 liver Anatomy 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 description 20
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 16
- 239000008103 glucose Substances 0.000 description 16
- 210000004369 blood Anatomy 0.000 description 15
- 239000008280 blood Substances 0.000 description 15
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 14
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 238000004393 prognosis Methods 0.000 description 10
- 238000001514 detection method Methods 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 8
- 238000008157 ELISA kit Methods 0.000 description 7
- 102000004877 Insulin Human genes 0.000 description 7
- 108090001061 Insulin Proteins 0.000 description 7
- 229940125396 insulin Drugs 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 238000007410 oral glucose tolerance test Methods 0.000 description 6
- 108010023302 HDL Cholesterol Proteins 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 241000191940 Staphylococcus Species 0.000 description 5
- 235000012000 cholesterol Nutrition 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 4
- 108010082126 Alanine transaminase Proteins 0.000 description 4
- 102000008070 Interferon-gamma Human genes 0.000 description 4
- 108010074328 Interferon-gamma Proteins 0.000 description 4
- 108010028554 LDL Cholesterol Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 4
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 4
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 229940109239 creatinine Drugs 0.000 description 4
- 229940044627 gamma-interferon Drugs 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 229940116269 uric acid Drugs 0.000 description 4
- 230000004584 weight gain Effects 0.000 description 4
- 235000019786 weight gain Nutrition 0.000 description 4
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 3
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 3
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 3
- 108090000193 Interleukin-1 beta Proteins 0.000 description 3
- 102000003777 Interleukin-1 beta Human genes 0.000 description 3
- 102000003814 Interleukin-10 Human genes 0.000 description 3
- 108090000174 Interleukin-10 Proteins 0.000 description 3
- 102000004889 Interleukin-6 Human genes 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 241000295644 Staphylococcaceae Species 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000003178 anti-diabetic effect Effects 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 235000009200 high fat diet Nutrition 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 229940100601 interleukin-6 Drugs 0.000 description 3
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 3
- 229960003105 metformin Drugs 0.000 description 3
- 230000000770 proinflammatory effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 230000008859 change Effects 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000002641 glycemic effect Effects 0.000 description 2
- 229940076144 interleukin-10 Drugs 0.000 description 2
- 235000021590 normal diet Nutrition 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 238000013218 HFD mouse model Methods 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 241000091577 Mexicana Species 0.000 description 1
- 102000006833 Multifunctional Enzymes Human genes 0.000 description 1
- 108010047290 Multifunctional Enzymes Proteins 0.000 description 1
- 101001033286 Mus musculus Interleukin-1 beta Proteins 0.000 description 1
- 101001033265 Mus musculus Interleukin-10 Proteins 0.000 description 1
- 101001076414 Mus musculus Interleukin-6 Proteins 0.000 description 1
- 101000648740 Mus musculus Tumor necrosis factor Proteins 0.000 description 1
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 208000021017 Weight Gain Diseases 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 230000003749 cleanliness Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000012528 insulin ELISA Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000013227 male C57BL/6J mice Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- KHPXUQMNIQBQEV-UHFFFAOYSA-N oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002633 protecting effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 102000014898 transaminase activity proteins Human genes 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention belongs to the field of foods and biological medicines, and discloses an application of staphylococcus albus in preparing a composition, wherein the composition is used for preventing and treating insulin resistance symptoms or type 2 diabetes mellitus, and the composition can be prepared into foods or biological medicines. The staphylococcus albus disclosed by the invention can obviously reduce the weight, reduce glycosylated hemoglobin, improve abnormal glucose tolerance, improve insulin resistance, improve inflammation, and regulate lipid metabolism and liver and kidney functions. The staphylococcus albus provided by the invention can effectively prevent and treat diabetes symptoms, has no obvious adverse reaction, is good in safety and has wide prospects.
Description
Technical Field
The invention belongs to the field of foods and biological medicines, and particularly relates to application of staphylococcus albus in preparation of a composition for preventing and treating insulin resistance symptoms and type 2 diabetes.
Background
Insulin resistance is one of the prominent features of type 2 diabetes and the fundamental link of pathogenesis. The incidence of type 2 diabetes increases year by year, and type 2 diabetes is a difficult disease to cure. Insulin resistance is curable by early intervention, strict diet control, exercise reinforcement and other life style dry prognosis. Can effectively prevent and treat insulin resistance, reduce the conversion rate of the insulin resistance to type 2 diabetes, and reduce the prevalence rate of type 2 diabetes. Insulin resistance or type 2 diabetes is often accompanied by weight gain, abnormal glucose tolerance, reduced insulin sensitivity and low grade inflammation. Therefore, lowering glycosylated hemoglobin, improving weight gain, abnormal glucose tolerance, insulin sensitivity and inflammation is a type 2 diabetes method.
Staphylococcus albus @Staphylococcus albus) Is a main raw material of the white grape fungus tablet approved to be marketed and is used for cough and excessive phlegm caused by respiratory diseases such as chronic bronchitis, and has no suggestion of application in a composition for preventing and treating insulin resistance symptoms and type 2 diabetes. That is, it is currently unclear whether staphylococcus albus have anti-diabetic biological functions.
In view of this, the present invention has been made.
Disclosure of Invention
The invention aims to provide application of staphylococcus albus in preparing a composition for preventing and treating insulin resistance symptoms or diabetes.
In order to achieve the above purpose, the following technical scheme is adopted:
the invention provides an application of staphylococcus albus in preparing a composition, wherein the composition is food, health care product or medicine, and the composition is used for preventing or treating insulin resistance symptoms or diabetes. The white staphylococcus is white staphylococcusStaphylococcus albus). In some embodiments, the diabetes is type 2 diabetes.
Preferably, the mass percentage of the staphylococcus albus in the composition is 0.1-100%.
Further, the composition is also a composition for one or two or more of weight reduction, glycosylated hemoglobin reduction, improvement of abnormal glucose tolerance or improvement of insulin sensitivity.
Further, for the use as described above, the composition is a medicament comprising staphylococcus albus as the main active ingredient.
Alternatively, the composition prepared by the above-described application may be used for one or more uses including weight reduction, glycosylated hemoglobin reduction, improvement of abnormal glucose tolerance, improvement of insulin sensitivity.
Alternatively, for the use as described above, the food, nutraceutical or pharmaceutical is a liquid or solid formulation.
Optionally, the medicament is an oral medicament.
Alternatively, the drug is a gastrointestinal administration formulation, based on gastrointestinal administration.
Alternatively, the gastrointestinal administration may be at the site of the oesophagus, stomach, small intestine, colon, rectum etc.
The invention also provides a composition prepared by the application.
Optionally, the medicament is powder, tablet, granule, capsule, solution, emulsion, suspension and the like. For example, in one embodiment, the drug is a tablet, administered by gavage; in some embodiments, the medicament is in the form of a capsule, for oral administration; in some embodiments, the drug is a solution or suspension, administered through the small intestine, colon, or rectum.
The beneficial effects of the invention are as follows:
the staphylococcus albus disclosed by the invention can obviously reduce the weight, reduce glycosylated hemoglobin, improve abnormal glucose tolerance, improve insulin resistance, improve inflammation, and regulate lipid metabolism and liver and kidney functions. The staphylococcus albus provided by the invention can effectively prevent and treat type 2 diabetes mellitus, has no obvious adverse reaction, is good in safety and has a wide prospect.
Drawings
Figure 1 is body weight of mice with 6 weeks of intervention;
FIG. 2 is a graph of Oral Glucose Tolerance Test (OGTT) results after intervention;
FIG. 3 is a quantification of area under OGTT curve (AUC of ITT) after intervention versus cumulative change in glycemic response;
FIG. 4 is a graph of insulin resistance test (ITT) results after intervention;
FIG. 5 is a quantification of area under the ITT curve (AUC of ITT) after intervention versus cumulative change in glycemic response;
FIG. 6 is insulin resistance index (HOMA-IR) of steady state model for dry prognosis;
FIG. 7 is glycosylated hemoglobin concentration for dry prognosis;
FIG. 8 is total cholesterol concentration after intervention;
FIG. 9 is the concentration of LDL cholesterol after intervention;
FIG. 10 shows the concentration of high density lipoprotein cholesterol in the dry state;
FIG. 11 shows glutamate pyruvate transaminase activity after intervention;
FIG. 12 shows glutamate oxaloacetate transaminase activity after intervention;
FIG. 13 is the serum creatinine concentration for dry prognosis;
FIG. 14 is blood urea nitrogen concentration for dry prognosis;
FIG. 15 is the blood uric acid concentration in the dry prognosis;
FIG. 16 is interleukin 1 beta concentration in the dry prognosis;
FIG. 17 is interleukin 6 concentration in the dry prognosis;
FIG. 18 is tumor necrosis factor alpha concentration in dry prognosis;
FIG. 19 is gamma interferon concentration in the dry prognosis;
FIG. 20 is the IL-10 concentration at the dry end.
Wherein NCD, HFD, LSA, HAS, met in fig. 1-20 respectively represent normal diet, high fat diet, low concentration white staphylococcus, high concentration white staphylococcus, metformin, 8 mice eachP < 0.05、**P < 0.01、***P< 0.001、****P <0.0001 indicates that the difference compared to the HFD group is statistically significant.
Detailed Description
In order to further describe the technical means and results adopted by the present invention to achieve the intended purpose, the following detailed description of the specific implementation, technical scheme and features according to the present invention will be given in the following preferred embodiments. The particular features, structures, or characteristics of the various embodiments in the description below may be combined in any suitable manner.
The following examples of the present invention were prepared from the following main materials and sources:
the white staphylococcus is white staphylococcusStaphylococcus albus(product number: TS 269665) is purchased from Ningbo Tex Tuo biotechnology Limited liability company, and the strain is also preserved in China general microbiological culture Collection center (CGMCC) with the preservation number of CGMCC No. 1.3374; glucose (cat# G8150) was purchased from Beijing Soy Bao technology Co., ltd; basal feed (lot number: 21103313) was purchased from Australian feed Co., ltd. In Beijing; high fat feeds (cat# D12492, 60% calories from fat) were purchased from Research diet, U.S.A.; insulin injections were purchased from Jiangsu wanbang Biochemical pharmaceutical Co., ltd; glucose detection kit (goods number: A154-1-1), total cholesterol detection kit (goods number: A111-1-1), low density lipoprotein cholesterol detection kit (goods number: A113-1-1), high density lipoprotein cholesterol detection kit (goods number: A112-1-1), glutamic pyruvic transaminase detection kit (goods number: C009-2-1), glutamic oxaloacetic transaminase detection kit (goods number: C010-2-1), creatinine detection kit (goods number: C011-2-1), uric acid detection kit (goods number: C012-2-1), urea nitrogen detection kit (goods number: C013-2-1) are all purchased from Nanjing's institute of biological engineering; mouse insulin ELISA kit (goods number: F5618B), mouse glycosylated hemoglobin ELISA kit (goods number: F5550B), mouse interleukin 1 beta ELISA kit (goods number: F5079B), mouse interleukin 6 ELISA kit (goods number: F5202B), mouse interleukin 10 ELISA kit (goods number: F5215B), mouse tumor necrosis factor alpha ELISA kit(cat# F5171B), mouse gamma interferon ELISA kit (cat# F5221B) were purchased from Jiangsu enzyme-free real Co., ltd; 1.5 mL centrifuge tube (Axygen Co., U.S.); glucometer (Shanghai Luo diagnostic products Co., ltd.); VORTEX-6 VORTEX oscillator (manufactured by Haifeng Chemie, inc. of Linbell instruments, inc.); 3K15 frozen high-speed centrifuge (Sigma Germany) and iD3 multifunctional enzyme-labeled instrument (America Valley molecular instrument (Shanghai) Co., ltd.).
Example 1: staphylococcus albus can reduce weight gain induced by high fat diet
40 male C57BL/6J mice at 6 weeks of age [ experimental animal license number: SCXK (jing) 2019-0009 was purchased from beijing vitelli laboratory animal technologies limited. Feeding conditions: no specific pathogen Specific Pathogen Free (SPF) grade cleanliness, room temperature of 20-22 ℃ and humidity of 60+/-5% is adopted, and 12 hours of light and shade are alternated, so that the drinking water can be eaten and drunk freely. Animal protocols in this experiment were approved by the beijing mexicana animal ethics committee and conducted with the animal experimental procedures under the guidance of the laboratory animal protection association.
Mice were weighed 7 days after being fed with basal feed, and were divided into Normal diet group (NCD), high-fat diet group (HFD), low-concentration white staphylococcus group (Low-dose) according to body weight (g) by random group designStaphylococcus albusLSA), high-concentration staphylococcus albus (High-dose)Staphylococcus albusHSA) and Metformin (metaformin, met), 8 mice per group. The NCD group was fed with basal feed, the HFD group, LSA group, HAS group and Met group were fed with high fat feed for 6 weeks, during which time the NCD group and HFD group were perfused with 10 mL/kg/d of normal saline, the LSA group was perfused with 45 mg/kg/d of staphylococcus albus, the HSA group was perfused with 95 mg/kg/d of staphylococcus albus, and the Met group was perfused with 300 mg/kg/d of metformin. Mice body weight was monitored weekly during the period.
The results are shown in figure 1, where the body weights of the NCD, LSA, HAS and Met mice were significantly lower than the HFD mice starting at week 3 post-intervention, indicating that the mice were able to significantly reduce weight gain after gavage with staphylococcus albus.
Example 2: staphylococcus albus can improve abnormal glucose tolerance and insulin resistance
An oral glucose tolerance test (Oral Glucose Tolerance Test, OGTT) was performed 6 weeks after the intervention to investigate the effect of staphylococcus albus on glucose tolerance after HFD induction. At week 6 after dosing, each group of mice was fasted without water withdrawal for 12 hours, weighed, tail drop blood was measured for fasting blood glucose (before glucose loading), and then a 20% glucose solution was administered by gavage at a dose of 2.0 g/kg, and at 30, 60, 90 and 120 min (after glucose loading), test mice were tested for tail blood and blood glucose using a blood glucose test paper and a blood glucose meter.
The results are shown in FIGS. 2 and 3, and the AUC of NCD, LSA, HAS and Met groups are lower than those of HFD groups in terms of the area under the curve of OGTT (Area under the curve, AUC)P <0.05 Indicating that staphylococcus albus can ameliorate abnormal glucose tolerance.
In addition, an insulin resistance test (Insulin Tolerance Test, ITT) was performed to investigate the effect of staphylococcus albus on insulin sensitivity after HFD induction. On week 6 after gastric lavage, each group of mice was fasted for 6 hours without water withdrawal, weighed, tail blood was drip measured for fasting blood glucose (pre-insulin injection), and insulin was intraperitoneally injected (0.5U/kg). The blood glucose test paper and the blood glucose meter were then used to test the blood glucose levels at 30, 60, 90 and 120 min (after insulin injection).
The results are shown in FIGS. 4 and 5, where the AUC of NCD, LSA, HAS and Met groups were lower than those of HFD groups as seen from the AUC of ITTP <0.01 HFD was shown to result in decreased insulin sensitivity and staphylococcus albus was able to improve insulin sensitivity.
After 6 weeks of intervention, each group of mice is fasted without water inhibition for 12 hours, the orbital venous plexus is taken, the collected blood stands for 30-60 min at room temperature, 4 ℃ and 16,200 g are centrifuged for 10 min, and the collected serum is stored at-80 ℃ and used for detecting subsequent observation indexes.
The mouse glucose and insulin concentrations were measured according to the kit procedure. According to the calculated insulin resistance index (HOMA-IR) of the steady state model: HOMA-ir=blood glucose (mmol/L) ×insulin (mIU/L)/22.5. The extent of insulin resistance was assessed using HOMA-IR. The results are shown in figure 6, where HOMA-IR was lower in NCD, LSA, HAS and Met groups than in HFD, indicating that staphylococcus albus was able to significantly improve insulin resistance.
Example 3: staphylococcus albus has antidiabetic effect
The glycosylated hemoglobin concentration of the mice was measured according to the kit procedure. The results are shown in figure 7, where HOMA-IR was significantly lower in NCD, LSA, HAS and Met groups than in HFD groups, indicating that staphylococcus albus was able to significantly reduce glycosylated hemoglobin concentration, which HAS anti-diabetic effects.
Example 4: staphylococcus albus can regulate lipid metabolism
The effect of staphylococcus albus on lipid metabolism in mice was examined by measuring the serum total cholesterol, low density lipoprotein cholesterol and high density lipoprotein cholesterol concentrations in mice according to the kit procedure. The results are shown in fig. 8-10, and compared with the NCD group, the HFD group has significantly increased total cholesterol, low density lipoprotein cholesterol and high density lipoprotein cholesterol concentrations, indicating that HFD induction causes lipid metabolism disorder in mice. Compared with the HFD group, the total cholesterol, the low-density lipoprotein cholesterol and the high-density lipoprotein cholesterol concentration of the LSA group are obviously reduced, and the total cholesterol concentration of the HAS group is obviously reduced, which indicates that the staphylococcus albus can regulate lipid metabolism.
Example 5: effect of Staphylococcus albus on liver function
The activity of glutamic pyruvic transaminase and glutamic oxaloacetic transaminase of the serum of the mice is detected according to the steps of the kit, so that the influence of the staphylococcus albus on the liver function of the mice is examined. As shown in FIGS. 11 and 12, the activities of glutamic pyruvic transaminase and glutamic oxaloacetic transaminase of NCD group, HFD group, LSA group, HAS group and Met group were in the normal range, and the activity of glutamic pyruvic transaminase of HAS group was lower than that of HFD groupP <0.01 Indicating that staphylococcus albus has liver function protecting effect.
Example 6: staphylococcus albus can regulate renal function
The effect of staphylococcus albus on the renal function of mice was examined by detecting serum creatinine, urea nitrogen and uric acid concentrations in accordance with the kit procedure. The results are shown in fig. 13-15, where there was no difference in serum creatinine and serum urea nitrogen concentrations in the NCD, HFD, LSA, HAS, and Met groups, and where the LSA mice had significantly lower serum uric acid concentrations than the HFD groups, indicating that staphylococcus albus was able to modulate kidney function.
Example 7: staphylococcus albus can improve inflammation
The effect of staphylococcus albus on HFD-induced inflammation in mice was examined by detecting the concentrations of the mouse serum pro-inflammatory factors interleukin 1 beta, interleukin 6, tumor necrosis factor alpha and gamma interferon, and anti-inflammatory factor interleukin 10 according to the ELISA kit steps. The results are shown in fig. 16-20, and the concentrations of pro-inflammatory factors interleukin 1 beta, interleukin 6, tumor necrosis factor alpha and gamma interferon in NCD group, LSA group, HAS group and Met group are all significantly lower than those in HFD group, and the concentrations of anti-inflammatory factors interleukin 10 are all significantly higher than those in HFD group, which indicates that white staphylococci can inhibit the release of pro-inflammatory factors to promote the release of anti-inflammatory factors, and indicate that white staphylococci have the effect of improving inflammation.
The above description is only of the preferred embodiments of the present invention; the scope of the invention is not limited in this respect. Any person skilled in the art, within the technical scope of the present disclosure, may apply to the present invention, and the technical solution and the improvement thereof are all covered by the protection scope of the present invention.
Claims (10)
1. Staphylococcus albus @Staphylococcus albus) Use of a composition for the preparation of a food, nutraceutical or pharmaceutical product for the prevention or treatment of symptoms of insulin resistance or type 2 diabetes.
2. The use according to claim 1, wherein the composition is also a composition for one or more of weight reduction, glycosylated hemoglobin reduction, improvement of impaired glucose tolerance or improvement of insulin sensitivity.
3. The use according to claim 1, characterized in that the mass percentage of said staphylococcus albus in said medicament is comprised between 0.1% and 100%.
4. The use according to claim 1, wherein the composition is a medicament, wherein the staphylococcus albus is one of the active ingredients.
5. The use according to claim 4, wherein the medicament is a powder, a tablet, a granule, a capsule, a solution, an emulsion or a suspension.
6. The use according to claim 4, wherein the pharmaceutical dosage form is a solid or liquid formulation.
7. The use according to claim 4, wherein the medicament is an oral medicament.
8. The use according to claim 4, wherein the medicament is a gastrointestinal administration formulation.
9. The use according to claim 8, wherein the gastrointestinal administration is via one or more sites of the oesophagus, stomach, small intestine, colon, rectum.
10. A composition prepared for use according to any one of claims 1 to 9, which is said food, nutraceutical or pharmaceutical.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310823003.4A CN116531410B (en) | 2023-07-06 | 2023-07-06 | Application of staphylococcus albus in preparation of composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310823003.4A CN116531410B (en) | 2023-07-06 | 2023-07-06 | Application of staphylococcus albus in preparation of composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116531410A true CN116531410A (en) | 2023-08-04 |
| CN116531410B CN116531410B (en) | 2023-10-03 |
Family
ID=87447525
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310823003.4A Active CN116531410B (en) | 2023-07-06 | 2023-07-06 | Application of staphylococcus albus in preparation of composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116531410B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117045686A (en) * | 2023-10-08 | 2023-11-14 | 首都医科大学附属北京友谊医院 | Application of bacteroides cellulolytic bacteria in preparation of medicine |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1416892A (en) * | 2001-11-09 | 2003-05-14 | 武汉春天生物工程股份有限公司 | Compound medicine tablet of biological bacteria powder for treating dyspneic cough |
| CN103405481A (en) * | 2013-08-24 | 2013-11-27 | 江苏神华药业有限公司 | Medicinal composition containing staphylococcus albus and preparation method thereof |
| RU2013151226A (en) * | 2013-11-18 | 2015-05-27 | Государственное научное учреждение Институт экспериментальной ветеринарии Сибири и Дальнего Востока Российской академии сельскохозяйственных наук (ГНУ ИЭВСиДВ Россельхозакадемии) | METHOD OF ACTIVATION OF CELLULAR IMMUNITY BY HOMEOPATHIC MEDICINES IN VITRO |
| CN108048367A (en) * | 2018-01-25 | 2018-05-18 | 仁和堂药业有限公司 | White staphylococcus powder and its application |
| WO2021239046A1 (en) * | 2020-05-28 | 2021-12-02 | 江苏康缘瑞翱生物医药科技有限公司 | Rhfgf21 fusion protein, polynucleotide encoding rhfgf21 fusion protein, composition containing rhfgf21 fusion protein, and use of rhfgf21 fusion protein |
| CN115227724A (en) * | 2022-09-21 | 2022-10-25 | 首都医科大学附属北京友谊医院 | Use of staphylococcus lentus in preparation of composition |
-
2023
- 2023-07-06 CN CN202310823003.4A patent/CN116531410B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1416892A (en) * | 2001-11-09 | 2003-05-14 | 武汉春天生物工程股份有限公司 | Compound medicine tablet of biological bacteria powder for treating dyspneic cough |
| CN103405481A (en) * | 2013-08-24 | 2013-11-27 | 江苏神华药业有限公司 | Medicinal composition containing staphylococcus albus and preparation method thereof |
| RU2013151226A (en) * | 2013-11-18 | 2015-05-27 | Государственное научное учреждение Институт экспериментальной ветеринарии Сибири и Дальнего Востока Российской академии сельскохозяйственных наук (ГНУ ИЭВСиДВ Россельхозакадемии) | METHOD OF ACTIVATION OF CELLULAR IMMUNITY BY HOMEOPATHIC MEDICINES IN VITRO |
| CN108048367A (en) * | 2018-01-25 | 2018-05-18 | 仁和堂药业有限公司 | White staphylococcus powder and its application |
| WO2021239046A1 (en) * | 2020-05-28 | 2021-12-02 | 江苏康缘瑞翱生物医药科技有限公司 | Rhfgf21 fusion protein, polynucleotide encoding rhfgf21 fusion protein, composition containing rhfgf21 fusion protein, and use of rhfgf21 fusion protein |
| CN115227724A (en) * | 2022-09-21 | 2022-10-25 | 首都医科大学附属北京友谊医院 | Use of staphylococcus lentus in preparation of composition |
Non-Patent Citations (2)
| Title |
|---|
| CHRISTOPHER WEIDENMAIER: "Staphylococcus aureus blocks insulin function", NAT MICROBIOL, vol. 03, no. 05 * |
| 吕晓春: "毛囊炎自治二方", 健康生活, no. 08 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117045686A (en) * | 2023-10-08 | 2023-11-14 | 首都医科大学附属北京友谊医院 | Application of bacteroides cellulolytic bacteria in preparation of medicine |
| CN117045686B (en) * | 2023-10-08 | 2024-02-13 | 首都医科大学附属北京友谊医院 | Application of bacteroides cellulolytic bacteria in preparation of medicine |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116531410B (en) | 2023-10-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN115227724B (en) | Use of staphylococcus lentus in preparation of composition | |
| CN116531410B (en) | Application of staphylococcus albus in preparation of composition | |
| CN110960539A (en) | Application of mulberroside A and derivatives thereof in preparation of medicine for protecting intestinal barrier | |
| US10183040B2 (en) | Method for regulation of lipid metabolism | |
| CN115243685A (en) | Pharmaceutical compositions for treating or preventing various inflammatory disorders | |
| CN109045070A (en) | A kind of composition for preventing and treating non-alcoholic fatty liver disease | |
| WO2021057680A1 (en) | Application of 2,4-dihydroxybenzoic acid or isomer thereof in related diseases or conditions caused by iron overload | |
| CN112587528B (en) | Pharmaceutical composition and application thereof in preparing medicines for improving insulin resistance and reducing blood sugar | |
| WO2022089591A1 (en) | Application of glucosamine in preparation of non-alcoholic fatty treatment drugs | |
| CN115282146A (en) | Application of tryptophol and pharmaceutically acceptable salt thereof in pharmacy | |
| CN116376740A (en) | Bifidobacterium longum with blood sugar reducing effect and application thereof | |
| CN114796321A (en) | Application of Tibetan medicine composition in preparing medicine for treating type 2 diabetes | |
| CN114831979A (en) | Application of 5-methoxyflavone in preparing medicine for treating obesity, hypercholesterolemia and fatty liver | |
| CN108771682A (en) | Betulinic acid promotes the application of fatty acid oxidation | |
| CN112457423A (en) | Natural extracted compound polysaccharide with function of improving insulin resistance and application thereof | |
| CN115400126B (en) | Composition and medical application thereof | |
| CN117797176B (en) | Application of clostridium bisporum in preparation of medicine for treating non-alcoholic fatty liver disease and medicine | |
| CN112426418A (en) | Composition for treating diabetes and application thereof | |
| CN115252607B (en) | Composition and application thereof in preparation of medicine for improving insulin resistance and reducing blood sugar | |
| WO2024067579A1 (en) | Use of ginkgo terpene lactone in preparing drug for preventing or treating diabetes and diabetic complication | |
| US20100144855A1 (en) | APPLICATION OF SEDOISOPROSAN FOR PREPARATION OF MEDICINE FOR TREATMENT OF HUMAN HBeAg POSITIVE CHRONIC HEPATITIS B | |
| CN117357512B (en) | Application of kaurene in preparation of medicines for preventing and/or treating metabolic syndrome | |
| CN115252638B (en) | Preparation method and application of quinoa dietary fiber for improving intestinal inflammation | |
| CN111529516B (en) | Application of spermidine in preparation of anti-hepatitis B virus drugs | |
| TWI698244B (en) | Use of a combination of small-molecule fucoidan and fucoxanthin for preparing a composition for improving non-alcoholic fatty liver |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |